Role of portal vein embolization in liver surgery: single centre experience in sixty-two patients.

04:33 EDT 31st August 2014 | BioPortfolio

Summary of "Role of portal vein embolization in liver surgery: single centre experience in sixty-two patients."

The extent of liver resection is limited by the residual functional reserve of the liver (FLR). The introduction of portal vein embolization (PVE), with the rationale of inducing hypertrophy of the FLR has significantly reduced morbidity and in particular the impact of postoperative liver failure (PLF). The objective of the study is to evaluate the feasibility and effectiveness of PVE in patients candidates to liver resections with high risk of PLF. Between January 2006 and December 2009, 62 patients suffering from primary or metastatic liver tumour, underwent PVE at the Department of Surgery-Liver Unit HSR. CT assessment of hepatic volume was performed in each patient, prior and 4 weeks after the procedure. The outcome was evaluated in terms of feasibility of surgery, FLR growth [calculated as: (FLR after PVE - FLR pre PVE) × 100/FLR pre PVE], morbidity and mortality associated with PVE and surgery. Of the 62 patients undergoing PVE, 6 (9.7%) did not benefit from surgery: of these, 4 showed spread of disease in the FLR at CT control, while in the remaining 2 adequate hypertrophy was not reached. The average volume of the FLR at the time of the procedure and after 4 weeks was 437.03 cc (±172.54) and 615.15 cc (± 187.49), respectively, with an average increase of 50.3% (±30.31). During the postoperative period, only 2 patients (3.2%) showed mild and transient signs of the PLF. The technique of PVE allows to performing, in an effective and safe way, major liver resections in patients with high risk of PLF.

Affiliation

Dipartimento di Chirurgia Generale e Specialistica, Unità Operativa Complessa Chirurgia Epatobiliare, Liver Unit, IRCCS H San Raffaele, Università Vita-Salute S. Raffaele, Via Olgettina 60, 20132, Milan, Italy, ratti.francesca@hsr.it.

Journal Details

This article was published in the following journal.

Name: Updates in surgery
ISSN: 2038-131X
Pages:

Links

PubMed Articles [30482 Associated PubMed Articles listed on BioPortfolio]

ALPPS Offers a Better Chance of Complete Resection in Patients with Primarily Unresectable Liver Tumors Compared with Conventional-Staged Hepatectomies: Results of a Multicenter Analysis.

Portal vein occlusion to increase the size of the future liver remnant (FLR) is well established, using portal vein ligation (PVL) or embolization (PVE) followed by resection 4-8 weeks later. Associa...

Gastric Coronary Vein to Portal Vein Reconstruction in Liver Transplant: Case Report.

Portal vein thrombosis is a common complication in end-stage liver diseases of candidates for liver transplant. Most portal vein thromboses can be removed with thrombectomy. However, if the thrombosis...

In situ split of the liver when portal venous embolization fails to induce hypertrophy: a report of two cases.

Introduction. Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been reported as an efficient alternative to portal vein embolization (PVE) to induce growth of the...

What is the Role of Bone Marrow-Derived Stem Cells in Hepatic Hypertrophy After Portal Vein Embolization?

Indications for portal vein embolization in perihilar cholangiocarcinoma.

Preoperative portal vein embolization (PVE) is often performed as a routine procedure before extended hepatectomy to minimize postoperative liver failure. However, the indications for PVE in perihilar...

Clinical Trials [6208 Associated Clinical Trials listed on BioPortfolio]

Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size a...

Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from di...

Evaluation of Probiotics in the Treatment of Portal Hypertension

This study is to evaluate the role of probiotics in the treatment of portal hypertension. In particular the role of probiotics on gut microbiota in liver cirrhosis patients will be studied...

Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection

Hepatectomy is still the treatment of choice for hepatocellular carcinoma. Part of the patients may present portal vein tumor thrombus (PVTT) after resection. PVTT might lead to upper gast...

Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein

The objective of this study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem cells (BMSCs) transplantation via portal vein in patients with early and midd...

Medical and Biotech [MESH] Definitions

Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.

A short thick vein formed by union of the superior mesenteric vein and the splenic vein.

Veins which return blood from the intestines; the inferior mesenteric vein empties into the splenic vein, the superior mesenteric vein joins the splenic vein to form the portal vein.

A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of esophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (JAMA 1995;273(23):1824-30)

Liver disease caused by infections with parasitic tapeworms of the genus ECHINOCOCCUS, such as Echinococcus granulosus or Echinococcus multilocularis. Ingested Echinococcus ova burrow into the intestinal mucosa. The larval migration to the liver via the PORTAL VEIN leads to watery vesicles (HYDATID CYST).

Search BioPortfolio:
Advertisement
Advertisement